Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A 26-week, Double-blind, Randomized Study in Participants With Overweight or Obesity Investigating the Added Contribution of Acarbose in EMP16 on Efficacy, Safety and Tolerability

NCT05934110 is registered in ClinicalTrials.gov with Empros Pharma AB as lead sponsor.

NCT NCT05934110
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05934110 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A 26-week, Double-blind, Randomized Study in Participants With Overweight or Obesity Investigating the Added Contribution of Acarbose in EMP16 on Efficacy, Safety and Tolerability
Lead sponsor
Empros Pharma AB
Phase
Phase 2
Overall status
Unknown status
Start date
April 18, 2023
Completion date
March 15, 2024
Enrollment
320 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

overweight or obesity